CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: February-01-13
Credit Expiration Date: February-01-14


David S. Geldmacher, MD, FACP
Charles and Patsy Collat Professor of Neurology
Director, Division of Memory Disorders and Behavioral Neurology
University of Alabama – Birmingham
Birmingham, AL

Carlos Rojas-Fernandez, BSc(Pharm), PharmD
Schlegel Research Chair in Geriatric Pharmacotherapy
Schlegel-UW Research Institute on Aging & School of Pharmacy
University of Waterloo
Kitchener, ON

Elizabeth M. Galik, PhD, CRNP
Assistant Professor
University of Maryland
School of Nursing
Baltimore, MD

Mary Campagnolo, MD, MBA, FAAFP, DABFM, CAQ-Geriatrics
Family Physician
Virtua-Family Medicine of Mansfield
Bordentown, NJ

Credit Hours

Family Physicians: 0.5 Prescribed credit
Nurses: 0.5 Contact Hours
Pharmacists: 0.5 Contact Hour (0.05 CEU)



Program Description

The burden of Alzheimer’s disease (AD) is well known; in the United States, $148 billion is spent on the care of more than 5 million individuals with AD—a number that is expected to climb to 7.7 million by the year 2030. It is now the sixth leading cause of death in Americans older than 65 years. While current therapies cannot halt the disease, active medical management can significantly improve the quality of life for patients with AD and their caregivers. The goal of this continuing education activity is to expand clinicians’ knowledge and competency in best practices related to the management of AD. This newsletter will consider the shortcomings of recent trials and discuss clinical implications.

Program Developer/Facilitator


Target Audience

Senior care clinicians including family physicians and other primary care physicians, long-term care (LTC) physicians and nurses, consultant pharmacists, and others interested in the care of older patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Identify the key properties of agents under investigation for the treatment of Alzheimer’s disease.
  2. Discuss new evidence from clinical trials of agents under investigation for Alzheimer’s disease.


It is the policy of the AAFP, ASCP, and NADONA to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Geldmacher discloses the following: Consultant: Bayer, Eisai, Glaxo, Janssen; Grant/Research Support: Baxter, BMS, Janssen, Novartis, Pfizer.
Dr. Rojas-Fernandez has no relevant financial conflicts to disclose.
Dr. Galik discloses the following: Consultant: Novartis.
Dr. Campangolo has no relevant financial conflicts to disclose.

Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Gerber has no relevant financial conflicts to disclose.

Ms. Barrett has no relevant financial conflicts to disclose.

Ms. Dornberger has no relevant financial conflicts to disclose.

Ms. Hines has no relevant financial conflicts to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

This Enduring Material activity, Clinical Insights in Geriatrics:
The Future of Alzheimer’s Disease Therapeutics, has been reviewed and is acceptable for up to 0.50 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins February 1, 2013. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-13-020-H01-P, has been assigned 0.5 Contact Hour (0.05 CEU). ASCP accreditation begins January 31, 2013.

NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 0.5 contact hour by NADONA/LTC.

Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 80% or better, and a statement may be printed immediately after passing the post-test.

There is no fee to participate in this educational activity.

Commercial Support Statements

This activity is supported by an educational grant from Forest Laboratories, Inc.


Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

  1. The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 30 minutes to complete.
  2. After the activity has finished, click on the "Post-test" button.
  3. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
  4. Please turn off all pop-up blockers to assure access to the educational activity.
  5. Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.

Certificate Fee



© 2013, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, ASCP, NJAFP, NADONA, or Forest Laboratories, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu